Lambda Pharm Spółka z Ograniczoną Odpowiedzialnością (KRS 0000697123, NIP 1231371116) is a Polish company, headquartered in Stara Iwiczna, Mazowieckie voivodeship. LAMBDA PHARM operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since October 3, 2017. LAMBDA PHARM's most recently reported net revenue was 115.3 K PLN for 2024.
Negative equity
Negative equity in 2 of 5 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Lambda Pharm
Identity
- Name
- Lambda Pharm Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- October 3, 2017
- Registry status as of
- December 17, 2025
- Latest entry
- December 16, 2025
- Founding act
- AKT NOTARIALNY Z DNIA 12 CZERWCA 2017 ROKU, REP. A NR 4444/2017 SPORZĄDZONY PRZEZ NOTARIUSZA PAWŁA ORŁOWSKIEGO Z KANCELA…
Articles of association history (1)
- AKT NOTARIALNY Z DNIA 12 CZERWCA 2017 ROKU, REP. A NR 4444/2017 SPORZĄDZONY PRZEZ NOTARIUSZA PAWŁA ORŁOWSKIEGO Z KANCELARII NOTARIALNEJ W WARSZAWIE PRZY UL. CHŁODNEJ 15, 00-891 WARSZAWA.
Activities
Main activity
47.73.ZDispensing chemist in specialised stores
Other activities
Address and contact
- Address
- UL. SŁONECZNA, 116A, 05-500, STARA IWICZNA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- PIASECZYŃSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.0823, 20.9955approx.
Risk and payment profile - Lambda Pharm
Credibility rating
59.5 / 100
Average credibility
Insolvency risk
Very low
Elevated threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/9 yrs
Board changes
0
0/9 yrs
PKD changes
0
0/9 yrs
Name changes
0
0/9 yrs
Data from 9 years of registry activity.
Credibility history
Payment reliability score from 2020–2024
Current: C (60/100)
Trend: improving (+24.6 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2020–2024
Current: 7.6 K PLN
Safe: 3.4 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Lambda Pharm
Founded
October 3, 2017
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
STARA IWICZNA
MAZOWIECKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
10.0 K PLN
165 shares total
Shareholders
4
shareholders
Board
3 people
Filed years
5 years
2020–2024 · profitable: 4/5
Registry entries
11
latest: December 16, 2025
Risk signals
Revenue
115.3 K PLN
2024
Net profit
9.4 K PLN
2024
Assets
38.7 K PLN
2024
Equity
1.5 K PLN
2024
Valuation
52.9 K PLN
High confidence
Market comparison Lambda Pharm
Comparison with PKD sector 47.73.Z
Market position (2024)
Sector median - total assets
Company - total assets
Public procurement
Trademarks
Reviews
Rate business credibility - Lambda Pharm.
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
